生物科技公司Beam Therapeutics (BEAM)股价在今晚夜盘大涨5.40%,报收28.43美元。据分析,该股涨势或与公司基因编辑技术的发展前景获市场看好有关。
作为基因编辑领域的创新者,Beam Therapeutics利用自主研发的碱基编辑技术,可精准编辑基因组中的单个碱基,无需引起DNA双链断裂。这项技术为创制新型基因药物开辟了全新途径,或可实现基因校正、修饰、激活、沉默等多种应用。
公司目前管线中有多个针对遗传性疾病的在研项目,如治疗镰状细胞病和β地中海贫血症的BEAM-101、针对α1抗酵素缺陷性肝病的BEAM-302等。随着这些项目的临床数据陆续公布,Beam Therapeutics的股价反应良好,前景值得期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.